Richard DiPaolo

Dr. Richard DiPaolo


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Gut
Verified
Journal Article
Open access
PDF file
KBKevin Bockerstett
Kevin Bockerstett
SLScott A Lewis
Scott A Lewis
KWKyle J Wolf
Kyle J Wolf
CNChristine N Noto
Christine N Noto
NJNicholas M Jackson
Nicholas M Jackson
RDRichard DiPaolo
Richard DiPaolo
Objective: Spasmolytic polypeptide-expressing metaplasia (SPEM) is a regenerative lesion in the gastric mucosa and is a potential precursor to intestinal metaplasia/gastric adenocarcinoma in a chronic inflammatory setting. The goal of these studies was to define the transcriptional changes associated with SPEM at the individual cell level in response to acute drug injury and chronic inflammatory damage in the gastric mucosa. Design: Epithelial cells were isolated from the gastric corpus of healthy stomachs and stomachs with drug-induced and inflammation-induced SPEM lesions. Single cell RNA sequencing (scRNA-seq) was performed on tissue samples from each of these settings. The transcriptomes of individual epithelial cells from healthy, acutely damaged and chronically inflamed stomachs were analysed and compared. Results: scRNA-seq revealed a population Mucin 6 (Muc6)+gastric intrinsic factor (Gif)+ cells in healthy tissue, but these cells did not express transcripts associated with SPEM. Furthermore, analyses of SPEM cells from drug injured and chronically inflamed corpus yielded two major findings: (1) SPEM and neck cell hyperplasia/hypertrophy are nearly identical in the expression of SPEM-associated transcripts and (2) SPEM programmes induced by drug-mediated parietal cell ablation and chronic inflammation are nearly identical, although the induction of transcripts involved in immunomodulation was unique to SPEM cells in the chronic inflammatory setting. Conclusions: These data necessitate an expansion of the definition of SPEM to include Tff2+Muc6+ cells that do not express mature chief cell transcripts such as Gif. Our data demonstrate that SPEM arises by a highly conserved cellular programme independent of aetiology and develops immunoregulatory capabilities in a setting of chronic inflammation.

1 July 2017 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
KBKevin Bockerstett
Kevin Bockerstett
RDRichard DiPaolo
Richard DiPaolo
Chronic inflammation caused by infection with Helicobacter pylori and autoimmune gastritis increases an individual's risk of developing gastric cancer. More than 90% of gastric cancers are adenocarcinomas, which originate from epithelial cells in the chronically inflamed gastric mucosa. However, only a small subset of chronic gastritis patients develops gastric cancer, implying a role for genetic and environmental factors in cancer development. A number of DNA polymorphisms that increase gastric cancer risk have mapped to genes encoding cytokines. Many different cytokines secreted by immune cells and epithelial cells during chronic gastritis have been identified, but a better understanding of how cytokines regulate the severity of gastritis, epithelial cell changes, and neoplastic transformation is needed. This review summarizes studies in both human and mouse models, describing a number of different findings that implicate various cytokines in regulating the development of gastric cancer.

21 August 2020 in Gastroenterology
Verified
Journal Article
Closed access
KBKevin A. Bockerstett
Kevin A. Bockerstett
SLScott A. Lewis
Scott A. Lewis
CNChristine N. Noto
Christine N. Noto
EFEric L. Ford
Eric L. Ford
JSJosé B. Saenz
José B. Saenz
RDRichard DiPaolo
Richard DiPaolo

3 December 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
LOLuciana H. Osaki
Luciana H. Osaki
KBKevin Bockerstett
Kevin Bockerstett
CWChun Fung Wong
Chun Fung Wong
EFEric L. Ford
Eric L. Ford
BMBlair B. Madison
Blair B. Madison
JMJason C. Mills
Jason C. Mills

1 April 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TNThanh-Long M. Nguyen
Thanh-Long M. Nguyen
SKShradha S. Khurana
Shradha S. Khurana
CBClifford J. Bellone
Clifford J. Bellone
BCBenjamin J. Capoccia
Benjamin J. Capoccia
JSJohn E. Sagartz
John E. Sagartz
RDRichard DiPaolo
Richard DiPaolo
Chronic inflammation is a major risk factor for cancer, including gastric cancers and other gastrointestinal cancers. For example, chronic inflammation caused by autoimmune gastritis (AIG) is associated with an increased risk of gastric polyps, gastric carcinoid tumors, and possibly adenocarcinomas. In this study, we characterized the progression of gastric cancer in a novel mouse model of AIG. In this model, disease was caused by CD4+ T cells expressing a transgenic T-cell receptor specific for a peptide from the H+/K+ ATPase proton pump, a protein expressed by parietal cells in the stomach. AIG caused epithelial cell aberrations that mimicked most of those seen in progression of human gastric cancers, including chronic gastritis followed by oxyntic atrophy, mucous neck cell hyperplasia, spasmolytic polypeptide-expressing metaplasia, dysplasia, and ultimately gastric intraepithelial neoplasias. Our work provides the first direct evidence that AIG supports the development of gastric neoplasia and provides a useful model to study how inflammation drives gastric cancer. Cancer Res; 73(7); 2117–26. ©2013 AACR.

12 October 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
CNChristine N. Noto
Christine N. Noto
SHStella G. Hoft
Stella G. Hoft
RDRichard DiPaolo
Richard DiPaolo
Mast cells are an essential part of the immune system and are best known as important modulators of allergic and anaphylactic immune responses. Upon activation, mast cells release a multitude of inflammatory mediators with various effector functions that can be both protective and damage-inducing. Mast cells can have an anti-inflammatory or pro-inflammatory immunological effect and play important roles in regulating autoimmune diseases including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. Importantly, chronic inflammation and autoimmunity are linked to the development of specific cancers including pancreatic cancer, prostate cancer, colorectal cancer, and gastric cancer. Inflammatory mediators released from activated mast cells regulate immune responses and promote vascular permeability and the recruitment of immune cells to the site of inflammation. Mast cells are present in increased numbers in tissues affected by autoimmune diseases as well as in tumor microenvironments where they co-localize with T regulatory cells and T effector cells. Mast cells can regulate immune responses by expressing immune checkpoint molecules on their surface, releasing anti-inflammatory cytokines, and promoting vascularization of solid tumor sites. As a result of these immune modulating activities, mast cells have disease-modifying roles in specific autoimmune diseases and cancers. Therefore, determining how to regulate the activities of mast cells in different inflammatory and tumor microenvironments may be critical to discovering potential therapeutic targets to treat autoimmune diseases and cancer.